Lithium cocrystal - Alzamend Neuro
Alternative Names: AL-001-Alzamend Neuro; LiProSal; LiProSalTM; Lithium salicylate/L-proline cocrystalLatest Information Update: 28 Apr 2026
At a glance
- Originator University of South Florida
- Developer Alzamend Neuro; Massachusetts General Hospital
- Class Alkali metals; Antidementias; Antidepressants; Antimanics; Antipsychotics; Light metals; Small molecules
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease; Bipolar disorders; Bipolar I disorders; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 20 Apr 2026 Alzamend Neuro initiates a phase I/IIa for Bipolar I disorder in USA (PO) (NCT07540338)
- 07 Apr 2026 Pharmacodynamics data from a phase-II trial in Alzheimer's disease released by Alzamend Neuro
- 07 Apr 2026 Alzamend Neuro plans confirmatory trials in Alzheimer's disease, Bipolar disorder, Major depressive disorder and Post-traumatic stress disorder